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Thedevelopment of simple, rapid, and low costmethods for early detection, identification, andmeasurement ofmultiple biomarkers
remains a challenge to improve diagnosis, treatment monitoring, and prognosis of cancer. Biosensing technology, combining
the properties of biological systems with functional advanced materials, guarantees rapid, reproducible, and highly sensitive cell
detection. In this study, we developed silicon-based biochips for prostate cancer PC3 cells detection by using cytokeratin 8/18
and Urotensin Receptor (UTR) as markers in order to obtain a biochip-based diagnostic system. Spectroscopic ellipsometry and
fluorescence microscopy were used to characterize surface homogeneity and chemical properties. Cell detection was investigated
by optical microscopy. Moreover, synthetic fluorescently labeled peptides were prepared and used for developing faster and lower-
cost identification assay compared with classic ELISA immunoassay. Results showed an effective immobilization of PC3 cells on
silicon surface and the specific recognition of these cells by fluorescent Urotensin II (4–11). In conclusion, this strategy could be
really useful as diagnostic system for prostate cancer.
1. Introduction
Prostate cancer is themost commonmalignant tumor inmen
and for this reason it is one of the most studied types from
the point of view of diagnostics and therapeutics. In the last
two decades, prostate cancer diagnosis has been based on
the detection of serum prostate-specific antigen (PSA) levels
and digital rectal examination. Unfortunately, the use of PSA
levels in clinical practice remains controversial since several
conditions (including medications, ejaculation, and prostate
manipulation) can alter its levels [1].
In malignant tumors, the presence of metastasis accounts
for the majority of cancer-related deaths owing to poor
response to anticancer therapies [2]; therefore early detection
of metastasis plays a key role in increasing survival in many
cancers [3]. Prostate cancer cells are frequently present in
peripheral blood circulation of men with advanced disease;
metastatic deposits occur preferably in the bones leading
to 84% of men’s death and are directly responsible for a
significant morbidity in time to death [4, 5]. Epithelial cells
of prostate rapidly bind the endothelium by an integrin-
mediated process [6, 7]. Once bound, they migrate through
the endothelial layer and then can infiltrate the bonemarrow,
peripheral blood, lymph nodes, stomach, or the penis to form
metastases. Prostate cancer cell lines can be classified as to
theirmetastatic destination: PC3, deriving by bonemetastasis
typically associated with advanced tumor and LNCaP that
derive by lymph nodemetastasis occurring in the early stages
of tumor [8].
In this light, these cells represent a good in vitromodel for
the design and evaluation of new assays to detect diagnostic
or prognostic markers in prostate cancer.
The characterization of ligand-receptors interactions in
tumor cells could become useful in the diagnosis of tumors
and in directing the choice of opportune therapeutic options
[9–13]. Epithelial cells in general, and epithelial derived tumor
cells in particular, express the epithelial cell adhesion protein
(EpCAM) and different cytokeratins (CKs), which are absent
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Figure 1: Schematic representation of biochip-based detection assay.
in normal white blood cells [14]. In particular, keratin 8
and keratin 18 (CK8/18) are the first pair to be expressed
in embryogenesis; they are involved in different regulatory
functions, such as protein targeting/trafficking and apoptosis
[14]. Further, CK8/18 are overexpressed in adenocarcinomas
and contribute to neoplastic transformation [14]. Growing
interest of scientist is shown also for Urotensin II (UT-II)
receptors. Urotensin II (UT-II) and its receptor (UTR) are
involved in the occurrence and development of different
epithelial cancers. It was reported that cell growth, motility,
and invasiveness in human bladder, prostate, and colorectal
cancer cells were regulated by U-II/UTR axis. Moreover, our
recent data suggested that UTR acts as a prognostic marker
in human prostate adenocarcinoma patients [15].
Biosensors and biochips are emerging as effective tools for
biomedical research and diagnostics having such advantages
as low costs and short analysis times, and they are more and
more used as commercial medical diagnostic devices [16].
Biosensors are analytical devices constituted by the
molecular recognition element and the transducer material.
The recognition elements can be biological molecules, such
as DNA single strand, proteins, enzymes, and even whole
cells that are coupled to different modes of transduction.
Transduction mode can include different approaches, such
as electrochemical, optical, and mass measurement. The
biological event induces a measurable change in a solution
property, which the transducer converts into an electrical
signal that can be quantified [17]. Biosensors are easy to
use and miniaturize and guarantee robust results compared
with classical analytical techniques such as immunohisto-
chemistry or ELISA [18]. In the last years, several label-
free biosensing devices have been developed in order to
detect clinical relevant molecules (including glucose, HCG,
or cardiac markers for diabetes and cardiac diseases) [19, 20].
Here, we propose developing a device based on crystalline
silicon-based biochips for prostate cancer PC3 cells detection
by using CK8/18 and UTR as markers in order to obtain a
new diagnostic system. This will lead to the development of
basic diagnostic kits that will be of help in the diagnosis of
cancer and/or to the discovery of novel markers.The strategy
includes the chemical functionalization of the silicon surface
by using bifunctional linker molecules, the anchoring to the
functionalized surface of specific antibodies, and the assay
of the biochip activity by evaluating its ability to reveal the
corresponding antibody expressed on membrane cells.
2. Materials and Methods
2.1. Biofunctionalization of Silicon Wafer. Crystalline silicon
(cSi) (0.001Ωcm resistivity, ⟨100⟩ oriented, 500 𝜇m thick)
surface was passivated by thermal oxidation at 1050∘C for
5 hours under nitrogen flux of 16.99 l/h and oxygen flux
of 0.2 l/min. Silicon dioxide was treated in piranha solution
(H2SO4 : H2O, 4 : 2) at room temperature (RT) for 30minutes
in order to activate Si-O-Si in Si-OH groups on silicon
surface. After extensive washes with distilled water and
drying under N2, chips were treated with a solution of 5%
APTES ((3-aminopropyl)triethoxysilane) (Sigma Aldrich) in
anhydrous toluene for 30 minutes at room temperature.
Subsequently, the chips were washed with anhydrous toluene
three times, cured on heater at 100∘C for 10 minutes, and
washed again twice with anhydrous toluene. The chips were
then treated with cross-linker BS3 (bis[sulfosuccinimidyl]
suberate) (Thermo Scientific) 1.6mM in PBS 1x pH = 7.4
at 4∘C for 5 h, washed three times with PBS 1x and once
with deionized water. Three chips were incubated at 4∘C
overnight with FITC- (fluorescein isothiocyanate-) labeled
protein A (PrA∗) (Sigma Aldrich) diluted in PBS 1x pH =
7.4 at three concentrations (sample C1: 1mg/mL; sample C2:
2mg/mL; sample C3: 3mg/mL) and then they were washed
three times with PBS 1x and once with deionized water. As
reference sample for fluorescence measurements a biochip
functionalized up to BS3 (sample C4) was used. After this
experiment, four new chips were functionalized as described
above using protein A (PrA) from S. aureus (Sigma Aldrich)
at 2mg/mL. Three chips were incubated with monoclonal
anti-CK8/18 antibody (CK3-3E4) from Miltenyi Biotech at
three different concentrations (sample A: 25 𝜇g/mL, sample
B: 50 𝜇g/mL, and sample C: 100 𝜇g/mL) at 4∘C overnight and
then they were washed three times with PBS 1x and once with
deionized water. As experimental control for detection assay
one chip was functionalized up to PrA (sample D).
2.2. Cell Culture. Thehumanprostate androgen-independent
PC3 cell line was obtained by ATCC. PC3 cells were grown in
DMEM supplemented with 10% heat-inactivated fetal bovine
serum, 20mM HEPES, 100U/mL penicillin, 100mg/mL
streptomycin, 1%L-glutamine, and 1% sodiumpyruvate. Cells
were cultured at 37∘C in a 5% CO2 -95% air environment in a
humidified incubator.
2.3. Immobilization of PC3 Cells. Samples A, B, C, andDwere
incubatedwith PC3 cells at a concentration of 5∗106 cells/mL
in PBS 1x for 2 hours (schematic representation of detection
assay of PC3 cells made on silicon-based biosensors was
shown in Figure 1) and then biochipswerewashed three times
with PBS 1x and once with deionized water.
2.4. Peptides Synthesis. Urotensin II (4–11) was obtained by
solid-phase peptide synthesis as previously reported [21].
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Scheme 1: Synthesis of Urotensin II (4–11) with 5(6)-carboxyfluorescein on solid-phase.
Incorporation of the 5(6)-carboxyfluorescein label at the N-
terminal position of Urotensin II (4–11) and H-Gly-Gly-
Urotensin II (4–11) was performed following the procedure
previously reported [22], that is, using 10 equiv of 5(6)-
carboxyfluorescein (Acros), 10 equiv of HOBt (GL Biochem,
China), and HBTU (GL Biochem, China) for 5 h resulting in
a yield of about 65% in the carboxyfluoresceination reaction.
Purification was achieved using a semipreparative reversed-
phase high-performance liquid chromatography (HPLC) C18
bonded silica column (Vydac 218TP1010; The Separations
Group Inc., Hesperia, CA, USA). The purified fluorescein-
peptide was 99% pure as determined by analytical reversed-
phase HPLC.The correct molecular weight was confirmed by
mass spectrometry and amino acid analysis. Peptide labeling
process is reported in Scheme 1.
2.5. Peptide Assay. The peptides were incubated at room
temperature for 30 minutes on biochips with higher immo-
bilization of PC3 cells (samples B and C) and then the
fluorescence was evaluated. The peptide without spacer arm
was incubated on sample C and the peptide with spacer arm
on sample B.
2.6. Spectroscopic Ellipsometry. Spectroscopic ellipsometry
(SE) measurements were performed by a Jobin Yvon
UVISEL-NIR phase modulated spectroscopic ellipsometer
apparatus, at an angle of incidence of 65∘ over the range
300–1600 nm with a resolution of 5 nm.
2.7. Optical Microscopy. Optical microscopy analysis was
made by means of a Leica DM6000 M microscope equipped
by Leica DFC 280 digital camera system. The magnification
used for acquisition was 10x and acquisition of images was
made in bright field.
2.8. Fluorescence Microscopy. Fluorescence analysis was per-
formed by means of a Leica Z16 APO fluorescence macro-
scope equipped with a camera Leica DFC300. The filter
Table 1: Spectroscopic ellipsometry measurement of chemical
layers growing.
Sample 𝑑ox (nm) 𝑑APTES (nm) 𝑑BS3 (nm) 𝑑PrA (nm)
C1 32.56 ± 0.02 6.1 ± 0.2 0.9 ± 0.1 1.5 ± 0.3
C2 33.17 ± 0.02 4.83 ± 0.06 0.6 ± 0.1 1.3 ± 0.1
C3 32.75 ± 0.01 4.48 ± 0.08 0.48 ± 0.03 1.44 ± 0.04
C4 32.05 ± 0.01 5.4 ± 0.2 0.7 ± 0.3 —
used for the acquisition was I3 consisting in a 450–490 nm
bandpass excitation filter, a 510 nm dichromatic mirror, and a
515 nm suppression filter.
3. Results and Discussion
Functionalization strategy started with evaluation of PrA
concentration needed to homogeneously cover the silicon
support surface. PrA properly interacts with the constant
fragment (Fc) region of the antibodies [22–24], and thus it
allows the right spatial orientation of the antibody on solid
supports. PrA has been bound on silicon surface by standard
silanization chemistry; the functionalization process is shown
in Figure 2. Silanol groups (Si-OH) were activated by piranha
solution, since they are more reactive with respect to Si-O-
Si bonds of silicon dioxide. A self-assembling silane, namely,
APTES, has been used in order to obtain a homogeneous
amino-terminal surface. The biochips were then treated with
a homobifunctional cross-linker, BS3, bringing a sulfo-𝑁-
hydroxysulfosuccinimide (sulfo-NHS) group that is able to
react with primary amines at pH 7–9 to form stable, covalent
amide bonds [25]. PrA has primary free amine groups on
the side chain of lysine, which can bind sulfo-NHS group on
biochip surface.
FITC-labeled PrA was used for functionalization of
biochips. Chemically modified surface of biochips was char-
acterized by fluorescence and ellipsometry measurements.
Results of spectroscopic ellipsometry are reported in Table 1;
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Figure 2: Reaction scheme of functionalization process.
in detail, about 5-6 nm of amino-terminal APTES silane is
present on each surface and an increase of 0.5–1 nmdue to the
addition of BS3 cross-linker can be observed.The quantitative
data are obtained by sampling the biochip surface in at least
three points; taking into account millimeter dimensions of
ellipsometer light spot, we found that the functionalization
is quite regular and reproducible on a macroscopic scale, at
least for chemical compound layers. Even if the three biochips
were functionalized by different concentrations of PrA∗, the
increase in layers thickness is very similar, ranging from 1.3
to 1.5 nm. In this view, we could conclude that ellipsometric
measurements are not useful for evaluation of the best PrA
concentration. On the other hand, fluorescence data, shown
in Figures 3(a) and 3(b), displayed quite different intensities
of fluorescence: sample C1 (chip functionalized by 1mg/mL
concentration of PrA∗) had a fluorescence (fluorescence
intensity = 370.9 a.u.) lower than sampleC2 and consequently
a lower degree of functionalization; sample C2 (2mg/mL
concentration of PrA∗) showed the presence of homogeneous
and strong fluorescence (fluorescence intensity = 389.8 a.u.);
sample C3 (chip with 3mg/mL concentration of PrA∗)
presented clearly visible fluorescent clusters, which explain
the highest fluorescence observed (fluorescence intensity =
460.8 a.u.) but also represent an excess of PrA that makes the
surface poorly homogenous. The control sample C4 (func-
tionalized up to BS3) did not show any autofluorescence (flu-
orescence intensity = 9.7 a.u.). Quantitative fluorescence data
Table 2: Cell counting of immobilized cells made by ImageJ
software.
Sample Number of cells
A (25 𝜇g/mL of CK3-3E4) 693
B (50 𝜇g/mL of CK3-3E4) 3604
C (100𝜇g/mL of CK3-3E4) 6858
D (CTR) 83
were summarized in Figure 3(b). As a result of homogeneous
and good degree of functionalization, silicon biochips were
functionalized by 2mg/mL PrA in subsequent experiments.
In the last step of biochip functionalization (Figure 2),
three different concentrations of antibody anti-CK8/18 (CK3-
3E4) were tested in order to evaluate biochips sensitivity
after interaction with PC3 cells that express CK8/18 on their
membrane. The specificity of CK3-3E4 antibody was previ-
ously tested by performing FACS analysis on blood samples,
as shown in Figure 7 where the binding event between the
cells expressing CK8/18 and the antibody CK3-3E4 is evident.
After PC3 cells incubation, silicon surfaces were observed
through optical microscopy and cells automatically counted
by ImageJ freeware software (Table 2). Due to function-
alization with different antibodies concentrations, biochips
showed very distinct ability in cell capture (Figure 4): biochip
with lower concentration of CK3-3E4 (sample A) showed
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Figure 3: (a) Images of biochips fluorescence after fluorescent PrA binding. Sample C1: biochip functionalized with PrA∗ at 1mg/mL. Sample
C2: biochip functionalized with PrA∗ at 2mg/mL. Sample C3: biochip functionalized with PrA∗ at 3mg/mL. Sample C4: reference biochip
functionalized up to BS3. In all images, error bar is 50 𝜇m. (b) Histogram representation for fluorescence intensity of samples obtained by
ImageJ software.
poor ability in binding cells, while biochips with higher
concentrations of CK3-3E4 (sample B and C) presented
increasing ability in blocking cells. The control biochip,
functionalized up to PrA (sample D), was not able at all to
detect cells. By plotting these data, we can estimate a kind of
device theoretical sensitivity relative to the ratio cells cap-
tured/antibody concentration. Figure 8 shows plot represen-
tation of cells number that was immobilized on biochips
against antibody concentration used during functionalization
process. OriginLab software was used to fit experimental
points in Figure 7 by the following equation:
𝑦 =
𝑎
1 + 𝑏𝑒−𝑘𝑥
. (1)
The first derivative of (1) is an estimation of sensitivity:
𝑑𝑦
𝑑𝑥
= 𝑎 ⋅
𝑘
4
= 157.5 ± 0.6 cell/ (𝜇g/mL) ,
(𝑎 = 6924 ± 5, 𝑘 = 0.0910 ± 0.0003) .
(2)
Functionalized biochips can be considered the first example
of a lab-on-chip device for the detection of circulating PC3
cells. In order to avoid false positives due to aspecific binding
event between biochip surface and other circulating cells, we
proposed a cell recognition assay through the use of synthetic
fluorescently labeled peptides that specifically bind UTR on
cell membrane. The specific binding of this labeled peptide
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Figure 4: Optical microscopy images after PC3 cells immobilization. Sample A: biochip functionalized with antibody concentration at
25 𝜇g/mL. Sample B: biochip functionalized with antibody concentration at 50𝜇g/mL. Sample C: biochip functionalized with antibody
concentration at 100𝜇g/mL. Sample D: biochip functionalized up to PrA. In all images, error bar is 50𝜇m.
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Figure 5: Schematic representation of (a) peptide assay made on generic cell immobilized on biosensor, (b) direct ELISA immunoassay
made on generic cell immobilized on biosensor, and (c) sandwich ELISA immunoassay made on generic cell immobilized on biosensor. The
schematization is in scale.
to UTR was previously demonstrated by performing binding
assay [15] [patent PCT/EP2008/051541].
A schematic representation of this assay compared with
common ELISA immunoassays is represented in Figure 5.
The peptide assay is one step and needs only one fluorescently
labeled peptide (Figure 5(a)), whereas sandwich ELISA (Fig-
ure 5(b)) needs antibody bound on plate surface that interacts
with antigen on cell membrane and then an enzyme-linked
antibody that produces labeled complexes (at least a three-
step assay), and direct ELISA immunoassay (Figure 5(c))
Journal of Sensors 7
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Figure 6: (a) Images of biochips fluorescence after FITC-labeled peptides binding. Sample B: biochip functionalized with antibody
concentration at 50𝜇g/mL and bonded with peptides with spacer arm. Sample C: biochip functionalized with antibody concentration at
100 𝜇g/mL and bonded with peptides without spacer arm. In both images, error bar is 50 𝜇m. (b) Histogram representation for fluorescence
intensity of samples obtained by ImageJ software.
uses antibody linked to enzyme that converts an uncolored
substrate in a labeled product (a two-step process) [26]. Both
ELISA immunoassays require high costs for reagents and
long times for performing experiments; on the contrary, the
proposed peptide assay requires only one incubation with the
labeled peptide, so that it could be fast and cheap. In detail,
twoFITC-labeled peptideswere used for cell recognition after
PC3 immobilization on biochip surface. The peptides used
represent two forms of fluorescent humanUrotensin II (4–11);
one was synthetized with a spacer arm (Gly-Gly) and the
other one without it, as reported in Scheme 1. Figure 6 shows
fluorescence images of sample B incubated with spacer arm
peptide and sample C incubated with peptide synthesized
without spacer arm together with their, respectively, fluo-
rescence intensities. Even if sample B shows a fluorescence
intensity quantitatively greater than sample C (fluorescence
intensity of sample B is 391 a.u.; fluorescence intensity of
sample C is 359 a.u.), the background fluorescence due to
binding of peptide with surface must be taken into account.
Sample C clearly exhibits a higher fluorescence signal on
immobilized cells and lower background fluorescence. Even
if both peptides identify PC3 cells bound on the biochip
surface, these results demonstrate that peptide synthesized
without spacer arm is more efficient and specific against false
positives.
4. Conclusions
In this experimental work, we explored the functionalization
strategy for detecting prostate cancer PC3 cells on crystalline
silicon biochip. Recent studies demonstrated that Urotensin
II receptor predicts the clinical outcome of prostate cancer
patients, so it is a helpful biomarker for PC3 recogni-
tion. Spectroscopic ellipsometry and fluorescent microscopy
quantified the thickness of biochemical layers and the rough-
ness of surfaces. Optical microscopy demonstrated that PC3
cell line could bind functionalized solid support and the num-
ber of detected cells critically depended on concentration of
anticytokeratin 8/18 grafted on silicon surface. Furthermore,
fluorescence data confirmed the use of synthetic labeled
Urotensin II (4–11) in rapid, easy, and low cost assay for
PC3 cells recognition due to their ability to bind selectively
UTR on cells membrane.These results demonstrated that the
proposed strategy could be really useful as diagnostic system
for prostate cancer. Moreover, even if the PC3 circulating
cells could be really few, there are a lot of microfluidic
8 Journal of Sensors
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Figure 8: Fitting of counted cell versus antibody concentration.
implemented methods to concentrate these cells and thus
make the proposed diagnostic test feasible [27].
Conflicts of Interest
The authors declare that there are no conflicts of interest
regarding the publication of this paper.
Acknowledgments
The authors gratefully thank Dr. Monica Terracciano for
interesting discussion about functionalization process.
References
[1] S. Loeb andW. J. Catalona, “What to do with an abnormal PSA
test,” Oncologist, vol. 13, no. 3, pp. 299–305, 2008.
[2] M. Cristofanilli, G. T. Budd, M. J. Ellis et al., “Circulating tumor
cells, disease progression, and survival in metastatic breast
cancer,” The New England Journal of Medicine, vol. 351, no. 8,
pp. 781–791, 2004.
[3] M. Feldstein and M. Zelen, “Inferring the natural time history
of breast cancer: Implications for tumor growth rate and early
detection,” Breast Cancer Research and Treatment, vol. 4, no. 1,
pp. 3–10, 1984.
[4] C. J. Logothetis, N. M. Navone, and S.-H. Lin, “Understanding
the biology of bone metastases: Key to the effective treatment
of prostate cancer,” Clinical Cancer Research, vol. 14, no. 6, pp.
1599–1602, 2008.
[5] I. G. McIntyre, K. Spreckley, and R. B. Clarke, “Optimization
of the reverse transcriptase polymerase chain reaction for the
detection of circulating prostate cells,” British Journal of Cancer,
vol. 83, pp. 992–997, 2000.
[6] S. Tai, Y. Sun, J. M. Squires et al., “PC3 is a cell line characteristic
of prostatic small cell carcinoma,” Prostate, vol. 71, no. 15, pp.
1668–1679, 2011.
[7] P. R. Dodds, V. J. Caride, and B. Lytton, “The role of vertebral
veins in the dissemination of prostatic carcinoma,”The Journal
of Urology, vol. 126, no. 6, pp. 753–755, 1981.
[8] G. Sardana, K. Jung, C. Stephan, and E. P. Diamandis, “Pro-
teomic analysis of conditioned media from the PC3, LNCaP,
and 22Rv1 prostate cancer cell lines: discovery and validation
of candidate prostate cancer biomarkers,” Journal of Proteome
Research, vol. 7, no. 8, pp. 3329–3338, 2008.
[9] P. S. Steeg, “Tumormetastasis: mechanistic insights and clinical
challenges,” Nature Medicine, vol. 12, no. 8, pp. 895–904, 2006.
[10] H. T. Tan, J. Low, S. G. Lim, and M. C. M. Chung, “Serum
autoantibodies as biomarkers for early cancer detection,” The
FEBS Journal, vol. 276, no. 23, pp. 6880–6904, 2009.
[11] M. Marra, G. Salzano, C. Leonetti et al., “Nanotechnologies to
use bisphosphonates as potent anticancer agents: the effects of
zoledronic acid encapsulated into liposomes,” Nanomedicine:
Nanotechnology, Biology, and Medicine, vol. 7, no. 6, pp. 955–
964, 2011.
[12] M. Caraglia, A. Budillon, P. Tagliaferri, M. Marra, A.
Abbruzzese, and F. Caponigro, “Isoprenylation of intracellular
proteins as a new target for the therapy of human neoplasms:
Preclinical and clinical implications,” Current Drug Targets, vol.
6, no. 3, pp. 301–323, 2005.
[13] M. Caraglia, M. Marra, C. Leonetti et al., “R115777 (Zarnes-
tra)/zoledronic acid (Zometa) cooperation on inhibition of
prostate cancer proliferation is paralleled by Erk/Akt inactiva-
tion and reduced Bcl-2 and bad phosphorylation,” Journal of
Cellular Physiology, vol. 211, no. 2, pp. 533–543, 2007.
[14] R. Moll, W. W. Franke, D. L. Schiller, B. Geiger, and R. Krepler,
“The catalog of human cytokeratins: patterns of expression in
normal epithelia, tumors and cultured cells,” Cell, vol. 31, no. 1,
pp. 11–24, 1982.
[15] P. Grieco, R. Franco, G. Bozzuto et al., “Urotensin II receptor
predicts the clinical outcome of prostate cancer patients and is
involved in the regulation of motility of prostate adenocarci-
noma cells,” Journal of Cellular Biochemistry, vol. 112, no. 1, pp.
341–353, 2011.
[16] F. S. Ligler and C. A. Rowe Taitt, Optical Biosensors, Elsevier,
Amsterdam, Netherlands, 2004.
Journal of Sensors 9
[17] A. F. Collings and F. Caruso, “Biosensors: recent advances,”
Reports on Progress in Physics, vol. 60, no. 11, pp. 1397–1445, 1997.
[18] S. U. Senveli and O. Tigli, “Biosensors in the small scale:
methods and technology trends,” IET Nanobiotechnology, vol.
7, no. 1, pp. 7–21, 2013.
[19] M. Tweedie, R. Subramanian, P. Lemoine et al., “Fabrication of
impedimetric sensors for label-free Point-of-Care immunoas-
say cardiac marker systems, with passive microfluidic delivery,”
in Proceedings of the Conference Proceedings. Annual Interna-
tional Conference of the IEEE Engineering in Medicine and
Biology Society, pp. 4610–4614, New York, NY, USA, August
2006.
[20] M. Vestergaard, K. Kerman, and E. Tamiya, “An overview of
label-free electrochemical protein sensors,” Sensors, vol. 7, no.
12, pp. 3442–3458, 2007.
[21] P. Grieco, A. Carotenuto, P. Campiglia et al., “A new, potent
urotensin II receptor peptide agonist containing a Pen residue
at the disulfide bridge,” Journal of Medicinal Chemistry, vol. 45,
no. 20, pp. 4391–4394, 2000.
[22] A. Lamberti, C. Sanges, N.Migliaccio et al., “Silicon-based tech-
nology for ligand-receptor molecular identification,” Journal of
Atomic, Molecular, and Optical Physics, vol. 2012, Article ID
948390, 5 pages, 2012.
[23] A. Lamberti, C. Sanges, L. Rotiroti et al., “The ligand-receptor
interactions based on silicon technology,” Current Topics in
Biotechnology, vol. 5, pp. 49–54, 2009.
[24] J. W. Goding, “Use of staphylococcal protein A as an immuno-
logical reagent,” Journal of Immunological Methods, vol. 20, no.
C, pp. 241–253, 1978.
[25] G. Mattson, E. Conklin, S. Desai, G. Nielander, M. D. Savage,
and S. Morgensen, “A practical approach to crosslinking,”
Molecular Biology Reports, vol. 17, no. 3, pp. 167–183, 1993.
[26] D. G. Wild, The Immunoassay Handbook: Theory and Applica-
tions of Ligand Binding, ELISA and Related Techniques, Elsevier,
Amsterdam, Netherlands, 2013.
[27] M. E. Warkiani, B. L. Khoo, D. S.-W. Tan et al., “An ultra-high-
throughput spiral microfluidic biochip for the enrichment of
circulating tumor cells,” Analyst, vol. 139, no. 13, pp. 3245–3255,
2014.
????????????????????????
?????????
???????????
??????????????????????????????
?????????????????????? ???????????
Robotics
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Active and Passive  
Electronic Components
Control Science
and Engineering
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
International Journal of
Rotating
Machinery
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation 
http://www.hindawi.com
 Journal of
???????????
Volume 201?
Submit your manuscripts at
https://www.hindawi.com
VLSI Design
Hindawi Publishing Corporation
http://www.hindawi.com Volume 201?
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Shock and Vibration
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Civil Engineering
Advances in
Acoustics and Vibration
Advances in
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Electrical and Computer 
Engineering
Journal of
Advances in
OptoElectronics
Hindawi Publishing Corporation 
http://www.hindawi.com
Volume 2014
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Sensors
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Modelling & 
Simulation 
in Engineering
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Chemical Engineering
International Journal of  Antennas and
Propagation
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Navigation and 
 Observation
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Distributed
Sensor Networks
International Journal of
